MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
Acquisition will advance company's ambition to provide a fully integrated and comprehensive solution for viral vector manufacturing Reinforces MilliporeSigma's continued commitment to shaping the future of gene therapies and other novel modalities BURLINGTON, Mass., May 22, 2024 BUSINESS WIRE )--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the signing of a definitive agreement to acquire Mirus Bio for US$ 600 million. Mirus Bio, part of Gamma Biosciences, is a life science company based in Madison, Wisconsin, USA that specializes in the development and commercialization of transfection reagents, such as TransIT-VirusGEN ® . Transfection reagents play a critical role in the production of viral vector-based gene therapies. "Viral vector-based cell and gene therapies have demonstrated their potential with more than 20 approvals over the last 10 years and will continue to advance, with a projected growth of 30 percent
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.MarketBeat
- Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes TrialBusiness Wire
- Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBEBusiness Wire
ARWR
Earnings
- 5/9/24 - Miss
ARWR
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 5/6/24 - Form 4
- ARWR's page on the SEC website